<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444223</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000529363</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-0304039-01</secondary_id>
    <nct_id>NCT00444223</nct_id>
  </id_info>
  <brief_title>Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants</brief_title>
  <official_title>The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron
      emission tomography (PET) scans.

      PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage
      III or stage IV non-small cell lung cancer and in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV
           non-small cell lung cancer (NSCLC) and in healthy participants.

        -  Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron
           emission tomography in patients with stage III or IV NSCLC.

      OUTLINE: This is a pilot study.

      Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body
      dynamic scans comprising positron emission tomography.

      Blood is collected during and after imaging to measure radioactivity.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date type="Actual">May 4, 2004</start_date>
  <completion_date type="Actual">May 15, 2008</completion_date>
  <primary_completion_date type="Actual">May 15, 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of fluorine F 18 FEQA</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>fluorine F 18 FEQA + positron emission tomography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fluorine F 18 FEQA + positron emission tomography</intervention_name>
    <arm_group_label>fluorine F 18 FEQA + positron emission tomography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet 1 of the following criteria:

          -  Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy

               -  Stage III or IV disease

               -  Clinically assessed with

          -  Healthy participant

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

